GGrantIndex
Sort

40,608 grants matching prostate cancer

MID ATLANTIC PROSTATE CANCER BANK

$628,670
George Washington University · U01 · FY2004 · CA

Defining the epigenetic landscape in human prostate cancer

$628,587
Matthew L Freedman · Dana-Farber Cancer Inst · R01 · FY2016 · CA

Defining the epigenetic landscape in human prostate cancer

$628,587
Matthew L Freedman · Dana-Farber Cancer Inst · R01 · FY2015 · CA

Motion-Resolved, Comprehensive Quantitative Tissue Characterization Using MR Multitasking

$628,575
Debiao Li · Cedars-Sinai Medical Center · R01 · FY2022 · EB

Motion-Resolved, Comprehensive Quantitative Tissue Characterization Using MR Multitasking

$628,575
Debiao Li · Cedars-Sinai Medical Center · R01 · FY2020 · EB

Evaluating Lung Cancer Screening Patterns and Outcomes through a North Carolina Registry

$628,514
Louise Henderson · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA

Adiposity and Outcomes of Clinically Localized Prostate Cancer

$628,470
Vincent L Freeman · University Of Illinois At Chicago · R01 · FY2010 · CA

Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early Stage Pancreatic Cancer

$628,354
Christian Maximillian Schmidt · Indiana University Indianapolis · U01 · FY2024 · CA

PET-determined prostate brachytherapy dosing using intraoperative image-guidance

$628,096
Daniel Song · Johns Hopkins University · R01 · FY2018 · CA

Managing Fatigue Using Virtual Reality for Post-Operative Lung Cancer Patients

$628,081
Amy Jude Hoffman · University Of Nebraska Medical Center · R01 · FY2018 · CA

10-year Comparative Effectiveness and Harms of Treatments for Prostate Cancer

$628,064
Daniel A Barocas · Vanderbilt University Medical Center · R01 · FY2021 · CA

Precision magnetic hyperthermia by integrating magnetic particle imaging

$628,016
Jeff W Bulte · Johns Hopkins University · R01 · FY2025 · CA

Multi-omic analysis of Myc-driven splicing for prostate cancer therapeutic development

$627,973
Owen N Witte · University Of California Los Angeles · R01 · FY2019 · CA

Delineating the underlying reasons for the racial disparity in gastric cancer incidence in the United States

$627,947
Meira Epplein · Duke University · R01 · FY2023 · CA

CLINICAL TRANSLATION OF HYPERPOLARIZED 13C-UREA FOR CANCER MR MOLECULAR IMAGING

$627,880
John Kurhanewicz · University Of California, San Francisco · R01 · FY2019 · CA

Effect of Aerobic Exercise on Genomic Signatures of Prostate Cancer Prognosis

$627,846
June Ml Chan · University Of California, San Francisco · R01 · FY2017 · CA

Pharmacogenetic Studies

$627,804
Neil E. Caporaso · Division Of Cancer Epidemiology And Genetics · ZIA · FY2009 · CA

Prognostic and Predictive Digital Tissue Image Assay for Prostate Cancer

$627,645
Anant Madabhushi · Emory University · R01 · FY2023 · CA

Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors

$627,573
Diana Zepeda-Orozco · Research Inst Nationwide Children'S Hosp · R01 · FY2024 · CA

Focal Laser Ablation of Prostate Cancer using MR/US Fusion

$627,518
Leonard Stephen Marks · University Of California Los Angeles · R01 · FY2017 · CA

Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making

$627,474
Matthew L Freedman · Dana-Farber Cancer Inst · R01 · FY2025 · CA

Addressing Misinformation to Promote Equity in Prostate Cancer Care

$627,381
Stacy Loeb · New York University School Of Medicine · R01 · FY2023 · CA

NCI NCTN- Network Lead Academic Participating Site: USC

$627,370
Heinz Josef Lenz · University Of Southern California · U10 · FY2016 · CA

Translational Pathology Core

$627,284
Peter A Jones · University Of Southern California · P30 · FY2013 · CA

Validation, Calibration, and Translation of Restriction Spectrum Imaging Signal Maps to enhance MRI diagnostic capabilities in Prostate Cancer

$627,248
Michael Andre Liss · University Of California, San Diego · R01 · FY2025 · CA